Mirum Pharmaceuticals sees FY23 revenue $186M-188M , consensus 185.4M

Mirum Pharmaceuticals provided its preliminary and unaudited estimates for full-year 2023 revenue and net product sales, corporate updates, and full-year 2024 outlook. “2023 was a transformative year for Mirum as we cemented our position as a leader in rare disease and dramatically advanced our operating and financial scale. We expanded our reach and impact through strong global adoption of LIVMARLI and the addition of CHOLBAM and CHENODAL,” said Chris Peetz, president and chief executive officer. “In the year ahead, we are excited about the growth prospects of all three commercial medicines, the potential label expansion opportunities for LIVMARLI and CHENODAL and key volixibat analyses in primary sclerosing cholangitis and primary biliary cholangitis.” Established a leading pediatric hepatology franchise with three commercial medicines..2023 estimated LIVMARLI net product sales of $141-143 M representing approximately 89% growth over 2022 LIVMARLI net product sales:Total expected net product sales of $69-71 million in Q4 including $41-43 million in LIVMARLI net sales and approximately $28 million in net sales from CHOLBAM and CHENODAL…